Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Hear Res. 2009 Mar;249(1-2):44–53. doi: 10.1016/j.heares.2009.01.007

Figure 7.

Figure 7

Diabetes increases thresholds assayed by ABRs, but decreases broad-band noise and tone burst thresholds in the IC. A) Dorsal and B) Ventral IC NFAEP thresholds; and C) ABR thresholds, recorded at 6 months following the start of the experiment (2-5 days prior to the IC recordings). Both diabetic subject groups showed significantly lower thresholds in both IC locations, while ABR thresholds were elevated compared to the control group, particularly at high frequencies. Statistically significant effects for subject groups was determined by two-way ANOVA (dorsal IC: F= 24.50, p<0.0001, df =2; ventral IC: F=36.04, p<0.0001, df=2). Post hoc Bonferroni tests in dorsal IC showed that controls had significantly higher thresholds vs. T1DM for 32 kHz, and vs. T2DM for 48 kHz. In ventral IC, controls were significantly different for 6, 20, 24, 32 and 36 kHz vs. T1DM, and 20 and 48 kHz vs. T2DM. Significant elevation of ABR thresholds for both types of diabetes was verified by two-way ANOVA (F= 8.66, p<0.001, df=2). Post hoc Bonferroni tests showed that ABR thresholds in the T2DM group were significantly higher at 48 kHz compared to controls. Data presented as mean ±SEM. n, number of mice in each group. For the ABR data, number of mice in each group was the same as in Fig. 2.